Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
921 to 940 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus. | Cell Insight | 2022 | 37193052 | PubTator, text mining | PubMed |
| MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53. | Acta Mater Med | 2022 | 36910255 | PubTator, text mining | PubMed |
| The role of viruses in HIV-associated lymphomas. | Semin Hematol | 2022 | 36805886 | PubTator, text mining | PubMed |
| Experts' consensus on the definition and management of high risk multiple myeloma. | Front Oncol | 2022 | 36755858 | PubTator, text mining | PubMed |
| Harnessing the immune system in the treatment of cutaneous T cell lymphomas. | Front Oncol | 2022 | 36713518 | PubTator, text mining | PubMed |
| Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development. | Curr Res Chem Biol | 2022 | 36712232 | PubTator, text mining | PubMed |
| Protein-Targeted Degradation Agents Based on Natural Products. | Pharmaceuticals (Basel) | 2022 | 36678543 | PubTator, text mining | PubMed |
| Therapeutic Strategies to Activate p53. | Pharmaceuticals (Basel) | 2022 | 36678521 | PubTator, text mining | PubMed |
| Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report. | Cureus | 2022 | 36636536 | PubTator, text mining | PubMed |
| Synthesis and Evaluation of Reactive Oxygen Species Sensitive Prodrugs of a NAMPT Inhibitor FK866. | Molecules | 2022 | 36615364 | PubTator, text mining | PubMed |
| Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma. | Int J Mol Sci | 2022 | 36614089 | PubTator, text mining | PubMed |
| How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. | Cancers (Basel) | 2022 | 36612152 | PubTator, text mining | PubMed |
| Targeted protein degradation by Trim-Away using cell resealing coupled with microscopic image-based quantitative analysis. | Front Cell Dev Biol | 2022 | 36601537 | PubTator, text mining | PubMed |
| Protein acylation: mechanisms, biological functions and therapeutic targets. | Signal Transduct Target Ther | 2022 | 36577755 | PubTator, text mining | PubMed |
| Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions. | Curr Res Pharmacol Drug Discov | 2022 | 36568268 | PubTator, text mining | PubMed |
| Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D2 synthase. | RSC Med Chem | 2022 | 36561070 | PubTator, text mining | PubMed |
| Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase. | Pharmaceutics | 2022 | 36559322 | PubTator, text mining | PubMed |
| Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. | Molecules | 2022 | 36557960 | PubTator, text mining | PubMed |
| Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma? | Int J Mol Sci | 2022 | 36555520 | PubTator, text mining | PubMed |
| Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter's Syndrome. | Cancers (Basel) | 2022 | 36551520 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=47